ProCE Banner Activity

MCL at First Relapse: Selecting a First- vs Second-Generation BTK Inhibitor

Clinical Thought
Ibrutinib and acalabrutinib are both active in relapsed MCL. Read how I consider safety, long-term data, and patient preferences when deciding between these BTK inhibitors.

Released: August 10, 2018

Expiration: August 09, 2019

No longer available for credit.

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca Pharmaceuticals

Pharmacyclics Inc

Faculty Disclosure

Primary Author

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, has disclosed that he has received fees for consulting from Abbvie, Bayer, Denovo Biopharma, Gilead, Karyopharm, OptumRx, Pharmacyclics/Janssen, and Spectrum and funds for research support from Abbvie, Acerta, Burroughs Wellcome Fund, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, TG Therapeutics, and V Foundation.